FIELD: medicine; chemistry.
SUBSTANCE: objects 1-3 are an antibody against transmembrane protein 180 (hereinafter – TMEM-180) or its antigen-binding fragment and an anti-cancer drug for the treatment of a malignant neoplasm other than hematological tumors, containing as its active ingredient an antibody or its antigen-binding fragment, including a substance connected to it that has anti-cancer activity. Objects 4 and 5 are nucleic acids encoding heavy and light chains or their CDR1-CDR3. Objects 6-8 are an expression vector, a transformant and a method for producing an antibody against TMEM-180 or its antigen-binding fragment. Objects 9 and 10 are a method and a set for testing a malignant neoplasm for recurrence or metastasis after treatment.
EFFECT: invention is aimed at binding the resulting antibody according to the invention to TMEM-180, specifically expressed in malignant cells, which allows using the antibody as an anti-cancer drug and to measure the amount of TMEM-180 in a sample when testing a malignant neoplasm for recurrence or metastasis after treatment.
21 cl, 12 dwg, 22 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| A NEW COMBINATION FOR USE IN THE TREATMENT OF MALIGNANT NEOPLASMS | 2016 |
|
RU2742494C2 |
| TREATMENT OF MALIGNANT NEOPLASM USING HUMANIZED CHIMERIC ANTIGEN RECEPTOR AGAINST BCMA | 2015 |
|
RU2751660C2 |
| BISPECIFIC ANTIBODIES SPECIFIC RELATIVELY TO COSTIMULATORY TNF-RECEPTOR | 2016 |
|
RU2761115C1 |
| MONOSPECIFIC AND BISPECIFIC PROTEINS WITH IMMUNE CHECKPOINT REGULATION FOR CANCER TREATMENT | 2018 |
|
RU2793167C2 |
| ANTIBODY AGENTS SPECIFIC TO HUMAN CD19, AND THEIR APPLICATIONS | 2016 |
|
RU2773317C2 |
| ANTI-PD-L1 AND IL-2 CYTOKINES | 2017 |
|
RU2769282C2 |
| PD-L1 SPECIFIC ANTIBODIES | 2017 |
|
RU2756236C2 |
| COMBINED THERAPY FOR MALIGNANT TUMOR TREATMENT | 2016 |
|
RU2733315C2 |
| BISPECIFIC ANTIGEN-BINDING MOLECULES CONTAINING ANTI-FAP CLONE 212 | 2019 |
|
RU2799429C2 |
| HER-2-DIRECTED ANTIGEN-BINDING MOLECULES CONTAINING 4-1BBL | 2019 |
|
RU2815451C2 |
